徐立,杨新春,王乐丰,葛永贵,王红石,李惟铭,陈牧雷,崔亮

• 1: 首都医科大学附属北京朝阳医院心脏中心首都医科大学心血管疾病研究所
• 2:首都医科大学附属北京朝阳医院心脏中心首都医科大学心血管疾病研究所
• 3:首都医科大学附属北京朝阳医院心脏中心首都医科大学心血管疾病研究所
• 4:首都医科大学附属北京朝阳医院心脏中心首都医科大学心血管疾病研究所

摘要(Abstract)：

目的探讨急性ST段抬高心肌梗死患者急诊直接PCI联合应用替罗非班期间发生血小板减少症的临床特点、处理及预后。方法2005年4月至2007年1月,355例急性ST段抬高心肌梗死患者接受急诊介入治疗时联合应用替罗非班,其中6例发生血小板减少症,发生率为1.69%。6例患者中,5例为男性,年龄50～72岁。回顾性分析该6例患者的相关临床情况。结果6例患者发生血小板减少的时间为接受替罗非班治疗后的1.5～12.0h,血小板最低值为(11～85)×109/L,其中重度1例,极重度1例。停用替罗非班24～120h后血小板计数值恢复正常。其中4例发生出血并发症,1例达到TIMI轻度出血标准;无输血小板和输红细胞病例,无再梗死及死亡病例。结论急性心肌梗死急诊介入治疗联合应用替罗非班过程中可以发生严重的血小板减少症,应该引起重视,在应用过程中需要加强监测。

关键词(KeyWords)： 血小板减少症;心肌梗死;血管成形术,经腔,经皮冠状动脉;血小板膜糖蛋白类

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐立,杨新春,王乐丰,葛永贵,王红石,李惟铭,陈牧雷,崔亮

参考文献(References)：

• [1]唐强,霍勇,陈明,等.盐酸替罗非班对AMI患者急诊PCI治疗中TIMI血流影响的临床研究.中国介入心脏病学杂志,2006,14:97-99.
• [2]杨新春,徐立,王乐丰,等.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注的影响研究.中国循环杂志,2006,21:4-6.
• [3]Dasgupta H,Blankenship JC,Wood GC,et al.Thrombocytope-nia complicating treatment with intravenous glycoproteinⅡb/Ⅲa receptor inhibitors:a pooled analysis.Am Heart J,2000,140:206-211.
• [4]Huxtable LM,Tafreshi MJ,Rakkar AN.Frequency and manage-ment of thrombocytopenia with the glycoproteinⅡb/Ⅲa receptor antagonists.Am J Cardiol,2006,97:426-429.
• [5]Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.J Interv Cardiol,2005,18:33-37.
• [6]The RESTORE Investigators.Effects of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.
• [7]Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable sign and symptoms(PRISM-PLUS)study investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myo-cardial infarction.N Engl Med,1998,338:1488-1497.
• [8]Berkowitz SD,Sane DC,Sigmon KN,et al.Occurrence and clin-ical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization.Evaluation of c7E3for the Prevention of Ischemic Complications(EPIC)Study Group.J Am Coll Cardiol,1998,32:311-319.
• [9]Bougie DW,Wilker PR,Wuitschick ED,et.al.Acute thrombo-cytopenia after treatment with tirofiban or eptifibatide is associa-tied with antibodies sepectific for ligand-occupied GPⅡb/Ⅲa.Blood,2002,100:2071-2076.
• [10]Patel S,Patel M,Din I,et al.Profound thrombocytopenia asso-ciated with tirofiban:case report and reviewof literature.Angiol-ogy,2005,56:351-355.
• [11]Tuhta AG,Yesildag O,Koprulu D.Tirofiban-associated acute thrombocytopenia.Acta Cardiol,2006,61:577-579.
• [12]Westerhout CM,Boersma E.Risk-benefit analysis of platelet gly-coproteinⅡb/Ⅲa inhibitors in acute coronary syndromes.Expert Opin Drug Saf,2003,2:49-58.